Dublin, Jan. 25, 2023 (GLOBE NEWSWIRE) — The “Type 2 Diabetes Treatment: Global Market Outlook” report has been added to ResearchAndMarkets.com’s offering.
In this report, the market has been segmented based on route of administration, therapy type and region. The report provides an overview of the global type 2 diabetes treatment market and analyses market trends. Using 2021 as the base year, it provides estimated market data for the forecast period of 2022 to 2027. Revenue forecasts for this period are segmented based on route of administration, therapy type and geography. Market values have been estimated based on the total revenue of type 2 diabetes therapies providers.
The report covers the market for type 2 diabetes treatment with regard to the therapy type across different regions. It also highlights major trends and challenges that affect the market and the vendor landscape. It estimates the global market for type 2 diabetes treatment in 2021, and then provides projections for the expected market size through 2027.
The scope of the study includes the various types of medicines involved in type 2 diabetes treatment and management. Blood glucose monitoring, diagnostic systems and devices, and insulin-delivery devices used in the treatment of type 2 diabetes, however, have been excluded from this study.
A comprehensive overview of the global market for the treatment of type 2 diabetes
Analyses of the global and regional market trends, with historic revenue data from 2019 to 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2027
Understanding of the current and future market potential for this innovation driven market, and areas of focus to forecast the market into various segments and sub-segments
Discussion of the industry growth driving factors and challenges that will shape the market for type 2 diabetes treatment as the basis for projecting demand in the next few years (2022-2027)
Estimation of the actual market size and revenue forecast for global type 2 diabetes treatment market, and corresponding market share analysis by therapy type, route of administration, end user, and region
Holistic review of the COVID-19 pandemic implications on the global market for treatment of type 2 diabetes
Review of the patent grants and patent applications on type 2 diabetes treatment solutions and related technologies
Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
Key Topics Covered:
Chapter 1 Market Outlook
1.1 Market Snapshot
Chapter 2 Executive Summary
Chapter 3 Market Overview
3.1 Type 2 Diabetes Overview
3.1.1 What is Type 2 Diabetes?
3.1.2 Prevalence and Epidemiology of Type 2 Diabetes
3.1.3 Diagnosing Type 2 Diabetes
3.1.4 Treatment for Type 2 Diabetes
3.2 Market Drivers
3.2.1 Rising Prevalence of Diabetes
3.2.2 Next Generation of Type 2 Diabetes Treatment
3.2.3 High Unmet Need
3.2.4 Premium Pricing
3.2.5 Collaborations and Licensing Agreements
3.3 Market Challenge
3.3.1 Loss of Exclusivity, Genericization and Pricing Pressure
3.3.2 Evolving Regulatory Scenario
3.4 Impact of Covid-19
Chapter 4 Emerging Trends and Opportunities
4.1 Patient Outcomes Beyond Glucose Control
4.2 Diabetes Technology With Digital Health
4.3 Growing Trend Toward Oral Antidiabetics
4.4 Growing Focus on Accessibility and Affordability of Medicine
Chapter 5 Market Breakdown by Route of Administration and Therapy Type
5.1 Type 2 Diabetes Treatment Market by Route of Administration
5.1.1 Market Size and Forecast
5.2 Injectable Therapies Market by Type
5.2.1 Insulin Therapy
5.2.2 Glucagon-Like Peptide 1 Therapy
5.2.3 Market Size and Forecast
5.3 Oral Medications Market by Drug Class
5.3.1 Dipeptidyl Peptidase-4 Inhibitors
5.3.2 Sodium-Glucose Cotransporter-2 Inhibitors
5.3.3 Glucagon-Like Peptide 1 Receptor Agonists
5.3.4 Other Oral Antidiabetic Medications
5.3.5 Market Size and Forecast
5.4 Type 2 Diabetes Treatment Market by Therapy Type
5.4.1 Market Size and Forecast
5.5 Insulin Therapy Market by Insulin Type
5.5.1 Market Size and Forecast
5.6 Non-Insulin Therapies Market by Drug Type
5.6.1 Market Size and Forecast
Chapter 6 Market Breakdown by Region
6.1 Type 2 Diabetes Treatment Market Size by Region
6.2 North America
6.5 Rest of the World
Chapter 7 Competitive Landscape
7.1 Global Market Shares of Leading Companies
7.2 Recent Key Developments
7.3 Blockbuster Diabetes Drug and Therapy Revenue
7.4 Facing the Patent Cliff
Chapter 8 Company Profiles
Boehringer Ingelheim International GmbH
Eli Lilly and Co.
Janssen Pharmaceuticals Inc. (Johnson & Johnson)
Merck & Co. Inc.
Novo Nordisk A/S
For more information about this report visit https://www.researchandmarkets.com/r/g2uxqw-2-diabetes?w=12
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Mackenzie Investments ("Mackenzie") today released its annual Mackenzie Investments Year-End ETF Report. The report studies the evolution of the exchange traded fund ("ETF") industry in Canada in 2022 and identifies the key trends that could impact the space in 2023 and beyond.
Following a daylong meeting of an expert advisory committee to the U.S. Food and Drug Administration, all Covid-19 vaccines and boosters will soon be made to address the most current strains.
A new era is about to begin at Toyota. The reasoning of the Japanese behemoth has always been that consumers were not ready to adopt electric vehicles. As a result, Toyota favored a policy of small steps.
Cathie Wood made her name by backing growth-oriented and cutting-edge stocks with her Ark Innovation ETF (ARKK) delivering huge returns for investors before and during the Covid-era. That all changed, however, as market sentiment shifted, and the past two years have seen the once-lauded investor’s reputation take a hit with the ARKK fund posting huge losses. But, so far, 2023 is turning out to be a turnaround story. ARKK is up nearly 20% since the turn of the year. Meanwhile, Wood has been loadi
Yahoo Finance’s Jared Blikre joins the Live show to break down Intel’s latest earnings report.
Chevron will launch a massive $75 billion share buyback and raise its dividend, the Dow Jones energy giant announced late Wednesday. The news comes ahead of fourth-quarter earnings due on Friday. Chevron stock advanced Thursday.
While the overall stock market direction so far this year remains up, the path ahead still presents plenty of potential headwinds. Inflation has yet to be properly tamed, the geopolitical map remains uncertain with Russia’s invasion of Ukraine still ongoing and Covid variants could reappear at any time. Add in the prospect for a fiery battle in Congress around raising the debt ceiling, and Oppenheimer’s Chief Investment Strategist John Stoltzfus thinks market volatility is “unlikely to leave the
The last year has been mixed for Apple, down about -10% on the year, but still outperforming the market
Yahoo Finance’s Ines Ferre joins the Live show to discuss the White House’s take on Chevron’s buyback program.
Shares of Microsoft (NASDAQ: MSFT) rose more than 3% on Thursday, as analysts defended the popular tech stock after its post-earnings decline, and investors grew increasingly excited about its artificial intelligence (AI) initiatives. Microsoft suffered a bit of a stock price swoon early on Wednesday despite delivering a relatively solid earnings performance, driven by strong gains in its cloud revenue. Piper Sandler analyst Brent Bracelin, in turn, believes that Microsoft's growth may have already bottomed.
Intel will reported its Q4 earnings after the bell on Tuesday, missing analysts' expectations.
Stocks moving in after hours: Intel, Hasbro, Visa
The Biden administration is poised to send a significant number of Abrams M1 tanks to Ukraine, according to The Wall Street Journal.
In this article, we will discuss the 10 stocks recently downgraded by analysts. If you want to see more such stocks on the list, you can directly visit Analysts Are Downgrading These 5 Stocks. Microsoft Corporation (NASDAQ:MSFT) is in the news after the company posted fiscal Q2 results. The company’s revenue outlook for the March […]
(Bloomberg) — What happens when you ask the hottest AI tool in the world to design an ETF that can beat the US equity market? It tells you the same thing every frustrated stock manager does.Most Read from BloombergHindenburg vs Adani: The Short Seller Taking On Asia’s Richest PersonNYSE Mayhem Traced to a Staffer Who Left a Backup System RunningWe Asked ChatGPT to Make a Market-Beating ETF. Here’s What HappenedHindenburg’s Short Sell Call Shaves $12 Billion Off Adani StocksIn a bid to see how c
Shares of Qualtrics International (NASDAQ: XM) popped as much as 34% this week, according to data from S&P Global Market Intelligence. The customer experience management software company posted a good earnings result for the fourth quarter and was buoyed by its majority shareholder SAP (NYSE: SAP) saying it was exploring a sale of its stake in the business. As of 4 p.m. ET on Thursday, Jan. 26, the stock is up 33.9% this week.
Berkshire Hathaway CEO Warren Buffett is widely considered one of the best stock pickers of all time, and for good reason. Here are three top Buffett stocks that could make you richer in 2023 and beyond. Ally Financial (NYSE: ALLY) is an automotive-oriented online bank.
Famed investor Cathie Wood, chief executive of Ark Investment Management, keeps unloading what was the No. 1 holding in Ark's flagship fund. Ark funds sold 683,698 shares of Exact Sciences Jan. 25, valued at $43.9 million as of that day's close. Exact Sciences' stock has lost 7% over the past year, but it has jumped 113% since Oct. 14, buoyed by strong earnings and the overall market's rally.
FISSION URANIUM CORP. ("Fission" or "the Company") is pleased to announce a winter program at its' 100% owned PLS property in Canada's Athabasca Basin region. The program will include geotechnical testing of key areas identified for surface infrastructure as identified in the Feasibility Study, including proposed stockpiles and mill locations. Also, 5 drill holes are designed to confirm groundwater modelling of certain sections of the R780E zone. Additionally, the company has staked a new, 11,14
Investors did not like the latest update from Alzheimer's drug maker Cassava Sciences (NASDAQ:SAVA). After showing excellent results from the first 50 patients treated with simufilam, the company's prospective Alzheimer’s drug in an open-label mid-stage study, the results from the full 200+ patients were not as good. Patients were given 2 100mg tablets a day over the course of one year on average, and these exhibited only a minimal change in the ADAS-Cog score. In the clinical research of Alzhei